Abstract
Blood type-incompatible transplantation has gained wide acceptance over the last decade. This is largely the result of B-cell-directed therapies aimed at modulating anti-blood group antibodies, which were the cause of the poor outcomes originally seen. Now rituximab (anti-CD20 and anti-B cell) has largely replaced splenectomy in preconditioning protocols, allowing for the wider implementation of ABO-incompatible transplants. Plasma exchange followed by intravenous immunoglobulin is also critical for the success of ABO-incompatible transplants. In this article, we describe the important contributions immunomodulatory drugs and antibody reduction therapies have made in achieving excellent outcomes in what was once an impenetrable barrier to transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
